补救性肝移植的疗效

目的 探讨补救性肝移植的适应证及其临床疗效.方法 回顾性分析2003年10月至2006年3月中山大学附属第三医院35例肝癌肝切除术后行肝移植患者的临床资料.比较补救性肝移植组(19例)和超补救性肝移植组(16例)患者的手术情况、术后并发症及预后等指标.计数和计量资料分别采用x2和t检验,非正态分布采用秩和检验,Kaplan-Meier法进行生存分析,生存率的比较采用Log-rank检验.结果 补救性肝移植组和超补救性肝移植组患者的无肝期、冷缺血时间、手术时间、术中出血量、术中输注红细胞量、术中输注新鲜冰冻血浆量、肝移植并发症发生率、再移植率分别为(32±9)min、(8.0±2.1)h、(7.6±1.5)h、2300ml、8 U、23 U、6/19、2/19和(34±7)min、(7.4±2.3)h、(7.4±2.0)h、2750ml、12 U、20U、4/16、1/16,两组比较,差异无统计学意义(t=0.726,-0.804,-0.366,Z=-0.348,-0.549,-0.149,x2=0.184,0.203,P＞0.05).补救性肝移植组和超补救性肝移植组患者围术期死亡率、术后肿瘤复发率分别为0、2/19和4/16、9/16,两组比较,差异有统计学意义(x2=5.363,8.426,P＜0.05).补救性肝移植组和超补救性肝移植组患者1、3、5年累积生存率分别为100%、84%、84%和75%、33%、33%;1、3、5年无瘤生存率分别为100%、89%、89%和48%、29%、19%,两组比较,差异有统计学意义(x2=11.58,19.31,P＜0.05).结论 补救性肝移植是肝癌治疗过程中的一种有效策略,米兰标准是目前补救性肝移植的最佳适应证.

Efficacy of salvage liver transplantation for patients with hepatoceliular carcinoma after liver resection

Objective To evaluate the efficacy and indications of salvage liver transplantation for patients with recurrent hepatecellular carcinoma(HCC)after liver resection.MethodsThe clinical data of 35 HCC patients who received salvage liver transplantation after liver resection at the Third Affiliated Hospital of Sun Yatsen University from October 2003 to March 2006 were retrospectively analyzed.All patients were divided into the salvage liver transplantation(SLT)group(n = 19)and extended SLT group(n = 16).Perioperative condition,postoperative complications and prognosis of the 2 groups were compared.The survival rate was analyzed and compared by the Kaplan-Meier method and Log-rank test,respectively.Results The anhepatic phase,ischaemic time,operation time,intraoperative blood loss,packed red blood cell transfusion,fresh frozen plasms transfusion,mobidity and retransplantation rate were(32 ± 9)minutes,(8.0 ± 2.1)hours,(7.6 ± 1.5)hours,2300 ml,8 U,23 U,6/19 and 2/19 in the SLT group,and(34 ± 7)minutes,(7.4 ± 2.3)hours,(7.4 ± 2.0)hours,2750 ml,12 U,20 U,4/16,1/16 in the extended SLT group,respectively,with no significant difference between the 2 groups(t=0.726,-0.804,-0.366,Z=-0.348,-0.549,-0.149,x2 =0.184,0.203,P＞0.05).The perioperative mortality,tumor recurrence rate were 0 and 2/19 in the SLT group,and 4/16 and 9/16 in the extended SLT group,with significant differences between the 2 groups(x2 = 5.363,8.426,P ＜ 0.05).The 1-,3-,5-year cumulative survival rates were 100%,84% and 84% in the SLT group,and 75%,33% and 33% in the extended SLT group.The 1-,3-,5-year tumor-free survival rates were 100%,89% and 89% in the SLT group,and 48%,29% and 19% in the extended SLT group.There were significant differences in the cumulative and tumor-free survival rates between the2 groups(x2 =11.58,19.31,P＜0.05).Conclusions The efficacy of SLT is satisfactory in the treatment of recurrent HCC.The optimal indication for SLT is Milan criteria.